↓ Skip to main content

A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer

Overview of attention for article published in BMC Cancer, May 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (76th percentile)
  • High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

news
1 news outlet

Citations

dimensions_citation
115 Dimensions

Readers on

mendeley
113 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer
Published in
BMC Cancer, May 2018
DOI 10.1186/s12885-018-4453-z
Pubmed ID
Authors

Yoshiki Hirooka, Hideki Kasuya, Takuya Ishikawa, Hiroki Kawashima, Eizaburo Ohno, Itzel B. Villalobos, Yoshinori Naoe, Toru Ichinose, Nobuto Koyama, Maki Tanaka, Yasuhiro Kodera, Hidemi Goto

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 113 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 113 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 12 11%
Researcher 10 9%
Student > Ph. D. Student 8 7%
Student > Bachelor 8 7%
Other 7 6%
Other 13 12%
Unknown 55 49%
Readers by discipline Count As %
Medicine and Dentistry 16 14%
Biochemistry, Genetics and Molecular Biology 8 7%
Immunology and Microbiology 6 5%
Pharmacology, Toxicology and Pharmaceutical Science 5 4%
Agricultural and Biological Sciences 4 4%
Other 13 12%
Unknown 61 54%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 April 2022.
All research outputs
#3,944,173
of 23,570,677 outputs
Outputs from BMC Cancer
#939
of 8,528 outputs
Outputs of similar age
#76,520
of 331,982 outputs
Outputs of similar age from BMC Cancer
#28
of 192 outputs
Altmetric has tracked 23,570,677 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,528 research outputs from this source. They receive a mean Attention Score of 4.4. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,982 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 192 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.